Antisoma appoints Michael Lewis as a Non-Executive Director

9 July 2008 London, UK: Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces the appointment of Mr Michael Lewis as a Non-Executive Director with immediate effect.

Mr Lewis is currently President for Europe, Middle East and Africa and was also Head of Global Marketing for the medical device company Gambro, with responsibility for USD 1.3 billion in sales and 1,000 staff. Before joining Gambro in 2002, he was CEO and Managing Director of Sybron, a specialist dental business based in Switzerland with 350 staff and a turnover in excess of USD 70 million. Mr Lewis has also held senior commercial positions at Boston Scientific International in Paris and Bard International in New Jersey.

Commenting on the appointment, Dr Barry Price, Chairman of Antisoma, said: "We are delighted to welcome Michael to our Board. His extensive experience in international healthcare marketing will be invaluable to Antisoma as we transition the business from drug development to commercialising our products over the coming years".

With regard to Mr Lewis's appointment, there are no disclosures required under paragraph 9.6.13 of the Listing Rules of the U.K. Listing Authority.

Enquiries:

Glyn Edwards, CEO
Daniel Elger, Director of Communications
Antisoma plc                         +44 (0)7909 915 068

Mark Court/Lisa Baderoon/Rebecca Skye
Dietrich
Buchanan Communications              +44 (0)20 7466 5000

Brian Korb
The Trout Group                         +1 646 378 2923

Background on Antisoma

Headquartered in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information.

Copyright © Hugin AS 2008. All rights reserved.